Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
2.600
-0.060 (-2.26%)
At close: Aug 13, 2025, 4:00 PM
2.570
-0.030 (-1.15%)
Pre-market: Aug 14, 2025, 9:28 AM EDT
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 11 or 55.00% compared to the previous year.
Employees
31
Change (1Y)
11
Growth (1Y)
55.00%
Revenue / Employee
n/a
Profits / Employee
-$614,452
Market Cap
155.69M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELDN News
- 7 days ago - Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation - GlobeNewsWire
- 14 days ago - Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025 - GlobeNewsWire
- 27 days ago - Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025 - GlobeNewsWire
- 7 weeks ago - Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City - GlobeNewsWire
- 3 months ago - Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 3 months ago - Undercovered Dozen: Gevo, Eledon, Dorian, Iridium + - Seeking Alpha
- 3 months ago - Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet - Seeking Alpha
- 5 months ago - Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results - GlobeNewsWire